Your browser doesn't support javascript.
loading
Mesenchymal stem cell dysfunction in diabetes.
Fijany, Arman; Sayadi, Lohrasb R; Khoshab, Nima; Banyard, Derek A; Shaterian, Ashkaun; Alexander, Michael; Lakey, Johnathan R T; Paydar, Keyianoosh Z; Evans, Gregory R D; Widgerow, Alan D.
Afiliación
  • Fijany A; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Sayadi LR; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Khoshab N; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Banyard DA; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Shaterian A; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Alexander M; UC Irvine Department of Surgery & Biomedical Engineering, Orange, CA, USA.
  • Lakey JRT; UC Irvine Department of Surgery & Biomedical Engineering, Orange, CA, USA.
  • Paydar KZ; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Evans GRD; UC Irvine Department of Plastic Surgery, Center for Tissue Engineering, Orange, CA, USA.
  • Widgerow AD; UC Irvine Department of Surgery & Biomedical Engineering, Orange, CA, USA.
Mol Biol Rep ; 46(1): 1459-1475, 2019 Feb.
Article en En | MEDLINE | ID: mdl-30484107
Diabetes mellitus (DM) is a chronic disease that results in a variety of systemic complications. Recently, stem cell-based therapies have been proposed as potential modalities to manage DM related complications. Mesenchymal stem cell (MSC) based therapies are often considered as an ideal stem cell-based treatment for DM management due to their immunosuppressive characteristics, anti-inflammatory properties and differentiation potential. While MSCs show tremendous promise, the underlying functional deficits of MSCs in DM patients is not well understood. Using the MEDLINE database to define these functional deficits, our search yielded 1826 articles of which 33 met our inclusion criteria. This allowed us to review the topic and illuminate four major molecular categories by which MSCs are compromised in both Type 1 DM and Type II DM models which include: (1) changes in angiogenesis/vasculogenesis, (2) altered pro-inflammatory cytokine secretion, (3) increased oxidative stress markers and (4) impaired cellular differentiation and decreased proliferation. Knowledge of the deficits in MSC function will allow us to more clearly assess the efficacy of potential biologic therapies for reversing these dysfunctions when treating the complications of diabetic disease.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Animals / Humans Idioma: En Revista: Mol Biol Rep Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Animals / Humans Idioma: En Revista: Mol Biol Rep Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos